logo.png
Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
February 13, 2019 09:15 ET | Oncotelic Inc
Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...
CC2.png
ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch
February 06, 2019 08:29 ET | ChemioCare
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company based on proprietary transdermal delivery, today announced the minipig safety and...
logo.jpg
HOVERINK BIOTECHNOLOGIES APPOINTS VSTOCK TRANSFER, LLC AS ITS TRANSFER AGENT AND REGISTRAR
July 11, 2018 10:24 ET | Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 11, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES Appoints VSTOCK TRANSFER, LLC as its TRANSFER AGENT AND REGISTRAR Hoverink Biotechnologies is currently developing IV and...
gmi 2018.png
U.S. Home Infusion Therapy Market worth over $13.5 billion by 2024: Global Market Insights, Inc.
June 11, 2018 07:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, June 11, 2018 (GLOBE NEWSWIRE) -- U.S. Home Infusion Therapy Market is poised to surpass USD 13.5 billion by 2024; according to a new research report by Global Market...
logo long.jpg
Global Generic Oncology Sterile Injectables Market to Surpass US$ 23.4 Billion by 2025 - Coherent Market Insights
May 24, 2018 08:55 ET | Coherent Market Insights
SEATTLE, May 24, 2018 (GLOBE NEWSWIRE) -- The global generic oncology sterile injectable market was valued at US$ 9,838.0 million in 2017 and is projected to exhibit a CAGR of 11.4% over the...
LIXTE.jpg
LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
February 09, 2018 09:45 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver,...
New Logo.png
PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMA
October 23, 2017 08:00 ET | Provectus Biopharmaceuticals Inc.
– Key impacts comprised worry/concern, altered clothing choices, and limitations to physical functioning – – Study results further support the clinical significance of Provectus’ ongoing,...
gmi logo.jpg
Pet Cancer Therapeutics Market worth over $300 million by 2024: Global Market Insights, Inc.
August 09, 2017 06:30 ET | Global Market Insights, Inc
Ocean View, Delaware, Aug. 09, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Pet Cancer Therapeutics Market By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats),...
NeoTherma Oncology Announces FDA Granted Its Vectron Thermal Device for Treatment of Pancreatic Cancer Breakthrough Device Designation within Expedited Access Pathway
April 04, 2017 10:06 ET | NeoTherma Oncology
WICHITA, Kan., April 04, 2017 (GLOBE NEWSWIRE) -- NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces that...
Allsup Cites New Study Tying Depression To Poorer Chemotherapy Outcomes In Lung Cancer Patients
January 23, 2017 09:30 ET | Allsup
BELLEVILLE, IL--(Marketwired - January 23, 2017) - A recent study of patients with lung cancer highlights the significance depression may have on treatment outcomes and the ability to work, according...